Anti-remodelling effect of canrenone in patients with mild chronic heart failure (AREA IN-CHF study): Final results

European Journal of Heart Failure

Volumn 11, Issue 1, 2009, Pages 68-76

  Boccanelli, Alessandro ^a   Mureddu, Gian Francesco ^a   Cacciatore, Giuseppe ^a   Clemenza, Francesco ^b   Di Lenarda, Andrea ^c   Gavazzi, Antonello ^d   Porcu, Maurizio ^e   Latini, Roberto ^f   Lucci, Donata ^g   Maggioni, Aldo Pietro ^g   Masson, Serge ^f   Vanasia, Massimo ^h   de Simone, Giovanni ⁱ  

^a SAN GIOVANNI ADDOLORATA HOSPITAL   (Italy)

^b MEDITERRANEAN INSTITUTE FOR TRANSPLANTATION AND ADVANCED SPECIALIZED THERAPIES ISMETT   (Italy)

^c UNIVERSITY HOSPITAL OF TRIESTE   (Italy)

^d OSPEDALI RIUNITI   (Italy)

^e BROTZU HOSPITAL   (Italy)

^f MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^g ANMCO RESEARCH CENTER   (Italy)

^h Therabel GiEnne Pharma SpA   (Italy)

ⁱ FEDERICO II UNIVERSITY HOSPITAL   (Italy)

Author keywords

Aldosterone receptor antagonists; Brain natriuretic peptide; Diastolic function; Ejection fraction; Heart failure

Indexed keywords

AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; BRONCHODILATING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANRENONE; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRIC ACID DERIVATIVE; PLACEBO; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; ALDOSTERONE ANTAGONIST; CREATININE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG WITHDRAWAL; FEMALE; HEART DEATH; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART VENTRICLE REMODELING; HOSPITALIZATION; HUMAN; HYPERKALEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; ADOLESCENT; BLOOD; CHRONIC DISEASE; CLASSIFICATION; DRUG EFFECT; ECHOGRAPHY; MIDDLE AGED; PATHOPHYSIOLOGY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALDOSTERONE ANTAGONISTS; CANRENONE; CHRONIC DISEASE; CREATININE; DOUBLE-BLIND METHOD; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; TREATMENT OUTCOME; VENTRICULAR REMODELING; YOUNG ADULT;

EID: 62449296975     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1093/eurjhf/hfn015     Document Type: Article

References (50)

1. Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol 1992;20:248-254.
2. Levine TB, Francis GS, Goldsmith SR, Simon A, Cohn JN. Activity of the sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relationship to hemodynamic abnormalities in congestive heart failure. Am J Cardiol 1982;49:1659-1666.
3. Mann DL. Mechanisms and models in heart failure. A combinatorial approach. Circulation 1999;100:999-1008.
4. Dzau VJ, Bernstein K, Celermajer D, Cohen J, Dahlof B, Deanfield J, Diez J, Drexler H, Ferrari R, Van Gilst W, Hansson L, Hornig B, Husain A, Johnston C, Lazar H, Lonn E, Luscher T, Mancini J, Mimran A, Pepine C, Rabelink T, Remme W, Ruilope L, Ruzicka M, Schunkert H, Swedberg K, Unger T, Vaughan D, Weber M. Pathophysiologic and therapeutic importance of tissue ACE: a Consensus report. Cardiovasc Drugs Ther 2002;16:149-160.
5. Francis GS. The relationship of the sympathetic nervous system and the renin angiotensin system in congestive heart failure. Am Heart J 1989;118:642-648.
6. Liu JL, Zucker IH. Regulation of sympathetic nerve activity in heart failure: a role for nitric oxide and angiotensin II. Circ Res 1999;84:417-423.
7. Cohn, Ferrari R, Sharpe N. Cardiac remodeling-concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. J Am Coll Cardiol 2000;35:569-582.
8. White HD, Norris RM, Brown MA, Brandt PW, Whitlock RM, Wild CJ. Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation 1987;76:44-51.
9. Vasan RS, Larson MG, Benjamin EJ, Evans JC, Levy D. Left ventricular dilatation and the risk of congestive heart failure in people without myocardial infarction. N Engl J Med 1997;336:1350-1355.
10. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327:685-691.
11. Wang TJ, Levy D, Benjamin EJ, Vasan RS. The epidemiology of ‘asymptomatic’ left ventricular systolic dysfunction: implications for screening. Ann Intern Med 2003; 138:907-916.
12. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJV, Michelson EL, Olofsson B, Ostergren J, for the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left ventricular ejection fraction. The CHARM-Preserved trial. Lancet 2003;362: 777-781.
13. Struthers AD. Aldosterone escape during ACE inhibitor therapy in chronic heart failure. Eur Heart J 1995;16:103-106.
14. Pitt B. ‘Escape’ of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: implications for therapy. Cardiovasc Drugs Ther 1995;9:145-149.
15. Tsutamoto T, Wada A, Maeda K, Mabuchi N, Hayashi M, Tsutsui T, Ohnishi M, Sawaki M, Fujii M, Matsumoto T, Matsui T, Kinoshita M. Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. J Am Coll Cardiol 2001;37:1228-1233.
16. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709-717.
17. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M, Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with LV dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-1321.
18. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW, Antman EM, Smith SC Jr, Adams CD, Anderson JL, Faxon DP, Fuster V, Halperin JL, Hiratzka LF, Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005;20: 156-215.
19. Cacciatore G, Boccanelli A, Mureddu GF, Maggioni AP, Latini R, Masson S, de Simone G, Investigatori dell’AREA IN-CHF. The AREA IN-CHF trial: antiremodeling effect of aldosterone receptors blockade with canrenone in mild chronic heart failure. Rationale and design. Ital Heart J 2005;6:66S-74S.
20. Remme WJ, Swedberg K. Guidelines for the diagnosis and treatment of CHF. Eur Heart J 2001;22:1527-1560.
21. Boccanelli A, Cacciatore G, Mureddu GF, de Simone G, Clemenza F, De Maria R, Di Lenarda A, Gavazi A, Latini R, Masson S, Porcu M, Vanasia M, Gonzini L, Maggioni AP, on behalf of the AREA IN-CHF Investigators. Baseline characteristics of patients recruited in the AREA IN-CHF study (AntiRemodeling Effect of Aldosterone Receptors Blockade with Canrenone in Mild Chronic Heart Failure). J Cardiovasc Med 2007;8:683-691.
22. Gosse P, de Simone G, Dubourg O, Gueret P, Schmieder R. Serial echocardiographic assessment of left ventricular mass: how blinded should readers be? J Hypertens 2004;22:1813-1818.
23. Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, Gutgesell H, Reichek N, Sahn D, Schnittger I. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 1989;2:358-367.
24. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, Reichek N. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986;57:450-458.
25. Ganau A, Devereux RB, Roman MJ, de Simone G, Pickering TG, Saba PS, Vargiu P, Simongini I, Laragh JH. Patterns of left ventricular hypertrophy and geometric remodelling in arterial hypertension. J Am Coll Cardiol 1992;19:1550-1558.
26. Wahr DW, Wang YS, Schiller NB. Left ventricular volumes determined by twodimensional echocardiography in a normal adult population. J Am Coll Cardiol 1983;1:863-868.
27. Municino A, de Simone G, Roman MJ, Cody RJ, Ganau A, Hahn RT, Devereux RB. Assessment of left ventricular function by meridional and circumferential endsystolic stress/minor axis shortening relations in dilated cardiomyopathy. Am J Cardiol 1996;78:544-549.
28. Mirsky I, Corin WJ, Murakami T, Grimm J, Hess OM, Krayenbuehl HP. Correction for preload in assessment of myocardial contractility in aortic and mitral valve disease. Application of the concept of systolic myocardial stiffness. Circulation 1988;78:68-80.
29. Cecconi M, Manfrin M, Zanoli R, Colonna P, Ruga O, Pangrazi A, Soro A. Doppler echocardiographic evaluation of left ventricular end-diastolic pressure in patients with coronary artery disease. J Am Soc Echocardiogr 1996;9:241-250.
30. Appleton CP, Galloway JM, Gonzales MS, Gaballa M, Basnight MA. Estimation of left ventricular filling pressures using two dimensional and Doppler echocardiography in adult patients with cardiac disease. Additional value of analyzing left atrial size, left atrial ejection fraction and the difference in duration of pulmonary venous and mitral flow velocity at atrial contraction. J Am Coll Cardiol 1993;22: 1972-1982.
31. Latini R, Masson S, Anand I, Judd D, Maggioni AP, Chiang YT, Bevilacqua M, Salio M, Cardano P, Dunselman PH, Holwerda NJ, Tognoni G, Cohn JN. Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure. The Valsartan Heart Failure Trial (Val-HeFT). Circulation 2002;106:2454-2458.
32. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
33. Zile MR, Baicu CF. Alterations in ventricular function: diastolic heart failure. In Mann DG, ed. Heart Failure. Philadelphia: Saunders; 2004.
34. Sadee W, Dagcioglu M, Riegelman S. Fluorometric microassay for spironolactone and its metabolites in biological fluids. J Pharm Sci 1972;16:1126-1129.
35. Modena MG, Aveta P, Menozzi A, Rossi R. Aldosterone inhibition limits collagen synthesis and progressive left ventricular enlargement after anterior myocardial infarction. Am Heart J 2001;141:41-46.
36. Cittadini A, Monti MG, Isgaard J, Casaburi C, Strömer H, Di Gianni A, Serpico R, Saldamarco L, Vanasia M, Saccá L. Aldosterone receptor blockade improves left ventricular remodeling and increases ventricular fibrillation threshold in experimental heart failure. Cardiovasc Res 2003;58:555-564.
37. Dart AM, Otterstad JE, Kirwan BA, Parker JD, de Brouwer S, Poole-Wilson PA, Lubsen J, on behalf of the Action Investigators. Predictive value of local and core laboratory echocardiographic assessment of cardiac function in patients with chronic stable angina: The ACTION study. Eur J Echocardiogr 2007;8: 275-283.
38. Vanderheyden M, Goethals M, Verstreken S, De Bruyne B, Muller K, Van Schuerbeeck E, Bartunek J. Wall stress modulates brain natriuretic peptide production in pressure overload cardiomyopathy. J Am Coll Cardiol 2004;44: 2349-2354.
39. Yuval R, Uziel K, Gordon N, Merdler A, Khader N, Karkabi B, Flugelman MY, Halon DA, Lewis BS. Perceived benefit after participating in positive or negative/neutral heart failure trials: the patients’ perspective. Eur J Heart Fail 2001; 3:217-223.
40. Tsioufis C, Stougiannos P, Taxiarchou E, Skiadas I, Chatzis D, Thomopoulos C, Lalos S, Stefanadis C, Kallikazaros I. The interplay between haemodynamic load, brain natriuretic peptide and left atrial size in the early stages of essential hypertension. J Hypertens 2006;24:965-972.
41. Douglas PS. The left atrium: a biomarker of chronic diastolic dysfunction and cardiovascular disease risk. J Am Coll Cardiol 2003;42:1206-1207.
42. Abhayaratna WP, Seward JB, Appleton CP, Douglas PS, Oh JK, Tajik AJ, Tsang TS. Left atrial size: physiologic determinants and clinical applications. J Am Coll Cardiol 2006;47:2357-2363.
43. Pitt B, White H, Nicolau J, Martinez F, Gheorghiade M, Aschermann M, van Veldhuisen DJ, Zannad F, Krum H, Mukherjee R, Vincent J, for the EPHESUS Investigators. Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J Am Coll Cardiol 2005;46:425-431.
44. Cicoira M, Zanolla L, Rossi A, Golia G, Franceschini L, Brighetti G, Marino P, Zardini P. Long term, dose-dependent effects of spironolactone on left ventricular function and exercise tolerance in patients with chronic heart failure. J Am Coll Cardiol 2002;40:304-310.
45. Berry C, Murphy N, DeVito G, Galloway S, Seed A, Fisher C, Sattar N, Vallance P, Hillis WS, McMurray J. Effects of aldosterone receptor blockade in patients with mild-moderate heart failure taking a beta-blocker. Eur J Heart Fail 2007;9: 429-434.
46. Farquharson CA, Struthers AD. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation 2000; 101:594-597.
47. Silvestre JS, Heymes C, Oubénaïssa A, Robert V, Aupetit-Faisant B, Carayon A, Swynghedauw B, Delcayre C. Activation of cardiac aldosterone production in rat myocardial infarction: effect of angiotensin II receptor blockade and role in cardiac fibrosis. Circulation 1999;99:2694-2701.
48. Ochs HR, Greenblatt DJ, Bodem G, Smith TW. Spironolactone. Am Heart J 1978; 96:389-400.
49. Sandall JM, Millership JS, Collier PS, McElnay JC. Development and validation of an HPLC method for the determination of spironolactone and its metabolites in paediatric plasma samples. J Chromatogr B Analyt Technol Biomed Life Sci 2006;839: 36-44.
50. Pitt B, Pitt G. Added benefit of mineralocorticoid receptor blockade in the primary prevention of sudden cardiac death. Circulation 2007;115:2976-2982.